GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 80 6. Mainstreaming out of school children Location Gurugram, Haryana | Beneficiaries: 120 The aim is to upgrade the targeted beneficiaries to grade level competencies by providing access to quality education, nutrition, and healthcare. At the end of the annual intervention period, the targeted beneficiaries are mainstreamed into conventional educational channels, in this case, government schools for continuing their education. 7. Holistic care for the vulnerable Location: Patna | Beneficiaries: 150 The programme is dedicated towards upliftment of underprivileged and deprived girls through free residential formal school education, co-curricular activities & vocational training. The mission is to prove that given equal opportunity, any girl has the potential to excel, irrespective of her family background. The programme has supported a residential school for 100 vulnerable girls and 50-day scholars in Patna. 8. Be A Changemaker (Orange day – Employee Volunteering programme) Volunteering is one of the key mechanisms that we have chosen to channelize our employees towards societal good. We strive to strengthen communities and bring the change that we wish to see in this world through volunteering. In 2021, we contributed over 5,200 volunteering hours towards varied social causes. For more details, please refer to the CSR Section on our website ( https://india-pharma.gsk.com/en-in/responsibility/ corporate-social-responsibility-programmes/) Transparency and disclosures compliances 1. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct: The below chart represents the complaints filed and pending as at the end of respective financial years. Pending complaints are resolved within your company defined timelines (*Note: Only those complaints from customers that relate to product quality are disclosed in the below chart. There may be more complaints from customers which may not be related to product quality. However, they are not disclosed here.) 58 191 340 0 4 41 0 100 200 300 400 Investors Employees and workers Customers* FY 2020-21 Complaints filed Complaints pending 87 155 432 0 27 39 0 100 200 300 400 500 Investors Employees and workers Customers* FY 2021-22 Complaints filed Complaints pending Overview of the entity’s material responsible business conduct issues The material issues are risks to your company but at the same time, if acted upon proactively, could provide significant opportunities for your company over its competitors in the industry. The identified risks are noted in your company’s risk register and are discussed periodically by the Compliance team with business owners, the Risk Management and Compliance Board (RMCB) and Risk Management committee of the board. Based on discussions and the estimated implications, appropriate mitigation actions are taken for material issues. Your company was conferred with the CNBC-TV18 Risk Management Award in the Pharma sector. This is a prestigious national award with over 500 top companies going through the nomination process set by an expert jury. Your company was recognized on evaluation against parameters pertaining to policy & framework, technology, people & culture, framework & governance, and testing & evaluation. The award recognizes the agility and resilience in serving millions Business Responsibility and Sustainability Report